17条政策支持昌平区医药健康产业发展

Core Viewpoint - The Beijing Municipal Science and Technology Commission, along with several departments, has issued measures to support the high-quality development of the pharmaceutical and health industry in Changping District from 2026 to 2028, focusing on innovation, talent development, and resource allocation [1][2]. Group 1: Policy Measures - The measures include 17 policies aimed at enhancing innovation capabilities, supporting global synchronous research and development of innovative drugs and medical devices, and expediting clinical trial processes [2]. - Financial support is provided for qualifying projects, with funding up to 30% of the total project investment, capped at 50 million yuan [1][2]. - The policies emphasize the integration of AI technology in drug development and healthcare applications, promoting AI-driven innovations [2]. Group 2: Industry Development Support - The measures aim to improve the efficiency of review and approval services to accelerate the market entry of innovative drugs and medical devices [2]. - Specific focus areas include synthetic biology manufacturing, cell and gene therapy, brain-machine interfaces, and high-end medical devices, with targeted support for technology service enterprises [2][3]. - The initiative encourages the development of diverse payment methods for innovative drugs and supports collaborations between health insurance companies and local pharmaceutical firms [2]. Group 3: Industrial Cluster Development - Plans are in place to establish a synthetic biology manufacturing industrial cluster and support the development of projects within designated areas [3]. - The initiative includes the creation of a cosmetics raw material information platform and a special incubation fund for brain-machine interfaces [3]. - The construction of an international medical device city is also prioritized, aiming to foster high-quality development and innovation in medical equipment [3].